Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants-Reference-Cited by-同舟云学术

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants

Published:2022-05-20 Issue:3 Volume:10 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Johansson Susanne¹^ORCID,Han David²,Hunt Thomas³,Björck Karin⁴,Florica Delia⁵,Gillen Michael⁶,Hall Jesse⁷,Erlandsson Fredrik⁸^ORCID

Affiliation:

1. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology & Safety Sciences AstraZeneca BioPharmaceuticals Research and Development Gothenburg Mölndal Sweden

2. Parexel Early Phase Clinical Unit Los Angeles Glendale California USA

3. PPD Development Austin Texas USA

4. Biometrics CVRM AstraZeneca BioPharmaceuticals Research and Development Gothenburg Mölndal Sweden

5. Patient Safety AstraZeneca BioPharmaceuticals Research and Development Gothenburg Sweden

6. Formerly of AstraZeneca BioPharmaceuticals Research and Development Gaithersburg Maryland USA

7. Formerly of Ardea Biosciences, Inc San Diego California USA

8. CVRM Late Clinical AstraZeneca BioPharmaceuticals Research and Development Gothenburg Mölndal Sweden

Funder

AstraZeneca Pharma Poland

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.929

Reference20 articles.

1. Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX

2. Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout

3. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD

4. Treatment of Hyperuricemia in Chronic Kidney Disease

5. Effect of Urate-lowering Therapies on Renal Disease Progression in Patients with Hyperuricemia

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The compelling role of allopurinol in hyperuricemia-induced epilepsy: Unrecognized like tears in rain;Brain Research Bulletin;2024-07

2. Combination Treatment with Verinurad and Allopurinol in CKD;Journal of the American Society of Nephrology;2024-02-20

3. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout;Expert Opinion on Drug Metabolism & Toxicology;2023-11-25

4. Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling;British Journal of Clinical Pharmacology;2023-01-02